Essential Facts on Medtronic – Do You Have a Position?

Large-cap Health Care company Medtronic has logged a -0.1% change today on a trading volume of 2,981,387. The average volume for the stock is 6,681,050.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Based in Dublin, Ireland the company has 95,000 full time employees and a market cap of $104,513,142,784. Medtronic currently offers its equity investors a dividend that yields 1.7% per year.

The company is now trading -13.68% away from its average analyst target price of $91.0 per share. The 27 analysts following the stock have set target prices ranging from $68.0 to $104.0, and on average give Medtronic a rating of buy.

Over the last 12 months MDT shares have declined by 0.0%, which represents a difference of -14.0% when compared to the S&P 500. The stock's 52 week high is $92.02 per share and its 52 week low is $68.84. Based on Medtronic's average net margin growth of 3.3% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 31,227,000 3,784,000 12 -25.0
2022 31,686,000 5,062,000 16 33.33
2021 30,117,000 3,630,000 12 -29.41
2020 28,913,000 4,806,000 17 13.33
2019 30,557,000 4,650,000 15 50.0
2018 29,953,000 3,104,000 10
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.